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Endothelial dysfunction is a potential target for (pharmaceutical) intervention of several systemic pathological conditions.
We investigated the feasibility of the EndoPAT to evaluate acute changes in endothelial function with repeated noninvasive
measurements and assessed its discriminating power in diﬀerent populations. Endothelial function was stable over a longer period
of time in renally impaired patients (coeﬃcient of variation 13%). Endothelial function in renally impaired and type 2 diabetic
patients was not decreased compared to healthy volunteers (2.9±1.4 and 1.8±0.3, resp., versus 1.8±0.5, P>0.05). The EndoPAT
did not detect an eﬀect of robust interventions on endothelial function in healthy volunteers (glucose load: change from baseline
0.08 ± 0.50, 95% conﬁdence interval −0.44 to 0.60; smoking: change from baseline 0.49 ± 0.92, 95% conﬁdence interval −0.47
to 1.46). This suggests that at present the EndoPAT might not be suitable to assess (changes in) endothelial function in early-
phase clinical pharmacology studies. Endothelial function as measured by the EndoPAT could be physiologically diﬀerent from
endothelial function as measured by conventional techniques. This should be investigated carefully before the EndoPAT can be
considered a useful tool in drug development or clinical practice.
1.Introduction
Endothelial dysfunction is an early predictor of cardiovas-
cular disease [1–3], and might be the causal pathological
mechanism of a variety of metabolic diseases, also referred to
as the common soil hypothesis [4]. Endothelial function has
been shown to be impaired in patients with coronary artery
disease, type II diabetes mellitus, hypertension, obesity, renal
failure,andhypercholesterolemia[5–9].Itisconceivablethat
improvement of endothelial function will be an important
target in the treatment of these conditions. Therefore,
availability of methodology that can be used to reliably assess
the eﬀects of (pharmacological) treatments on endothelial
function is of critical importance.
Endothelial dysfunction is commonly described as the
inability of the artery to suﬃciently dilate in response to
an appropriate endothelial stimulus. It can be assessed by
measurement of the arterial pulse wave at a ﬁnger artery or
by the measurement of ﬂow-mediated dilation (FMD) of the
brachial artery after occlusion of the blood ﬂow. Although
the exact mechanisms causing FMD are not entirely known,
the main mechanism inducing FMD is thought to be an
increase in shear stress, leading to the release of nitric oxide
from endothelial cells which causes blood vessel dilation
[10]. Currently, FMD is assessed clinically in a noninvasive
manner using high-resolution ultrasound of the brachial
artery. The technique is widely used and has been shown to
be a suitable tool to assess endothelial dysfunction. However,
the method has several disadvantages: it is operator depen-
dent [11], and as FMD is measured at one arm only, there
are no possibilities to correct for potential measurement-
induced changes in the systemic hemodynamics, such as
those resulting from alterations in the autonomous nervous
system tone. To overcome these problems, the EndoPAT was
developed. This device allows non-invasive measurement
of vasoreactivity without the disadvantages of conventional
ultrasound measurement. The EndoPAT detects plethysmo-
graphic pressure changes in the ﬁnger tips caused by the
arterial pulse and translates this to a peripheral arterial tone
(PAT). Endothelium-mediated changes in vascular tone after
occlusion of the brachial artery are reﬂecting a downstream
hyperemic response, which is a measure for arterial endothe-
lialfunction[12].Measurementsonthecontralateralarmare2 International Journal of Vascular Medicine
used to control for concurrent nonendothelium-dependent
changes in vascular tone. In addition, the EndoPAT provides
am e a s u r ef o ra r t e r i a ls t i ﬀness: the augmentation index
(AI). In theory, the EndoPAT could be a useful device in
clinical research as the test is easy to perform, not operator-
dependent, and with comprehensive automatic analysis. In
a group of 89 adult patients suﬀering from chest pain,
peripheral arterial tone correlated positively with FMD [12].
In the Framingham study, a signiﬁcant inverse relation was
observed between endothelial function as determined by the
EndoPAT (“EndoScore” or reactive hyperemia index, RHI)
and multiple cardiovascular risk factors (male sex, body
mass index, total/HDL cholesterol, diabetes, smoking, and
lipid-lowering treatment) [13]. The EndoScore was reported
to be signiﬁcantly decreased in patients with coronary
artery disease, hypertension, hyperlipidemia, diabetes, glu-
cose intolerance, and tobacco users (group sizes of 15 to 70
subjects) [12, 14–18]. Several EndoPAT studies have demon-
strated an improvement in endothelial function as a result
of lifestyle modiﬁcation (smoking cessation, and dietary
change) [19–22] or prolonged pharmacological intervention
[23, 24]. However, there is only limited information on the
performance of the EndoPAT for repeated measurements in
arelativelyshorttimeframe.Thisinformationispertinentas
in many clinical (pharmacology) studies repeated measures
are performed in populations consisting of 6 to 12 subjects.
Therefore, we performed a series of experiments to
investigate the feasibility of the EndoPAT to evaluate acute
changes in endothelial function and arterial stiﬀness with
repeated measurements and to assess the discriminating
power of the EndoPAT in diﬀerent populations. First, we
investigated the variability of endothelial function and
arterial stiﬀness, as measured by the EndoPAT, in patients
with chronic kidney failure on three diﬀerent days. Endothe-
lial function, as assessed by high-resolution ultrasound, is
known to be severely impaired in this patient population,
despite intensive treatment (30–60% reduction) [25–28].
In addition, we measured endothelial function and arterial
stiﬀness in patients with diabetes mellitus type 2, another
patient population with a strongly reduced endothelial reac-
tivity as determined using conventional techniques (30–35%
reduction) [29–31]. Finally, we investigated the capability of
the device to detect changes in endothelial function induced
by two acute and robust interventions (smoking and glucose
administration) in healthy volunteers. Cigarette smoking
acutely impairs endothelial function in healthy volunteers
by causing oxidative stress and reducing the production of
nitric oxide due to the free radicals present in cigarette
smoke [2, 32]. Also high blood glucose levels lead to an
attenuated endothelial function, as has been demonstrated
by plethysmography and high-resolution ultrasound [33,
34].
2.MaterialsandMethods
The experiments were approved by the Medical Ethics
Committee of Leiden University Medical Center (LUMC).
Endothelial function and arterial stiﬀness were assessed
in 6 renal patients (creatinine clearance between 30 and
70mL/min) and 16 patients with diabetes mellitus type 2
(8 using metformin and 8 using metformin plus sulfony-
lurea). Intervention studies were performed in apparently
healthy males and females, not using any medication. In all
experiments, subjects were fasted for at least 3 hours before
EndoPAT measurements.
2.1. Protocol. Reactive hyperemia index (RHI), which is a
measure for endothelial function, and augmentation index
(AI), which is a measure for arterial stiﬀness, were assessed
using the EndoPAT 2000 device (Itamar Medical, Israel).
Both measures were calculated using a computerised auto-
mated algorithm (software version 3.1.2) provided with
the device. Measurements were performed according to
the manufacturer’s instructions. Brieﬂy, the subjects were
in supine position for a minimum of 20 minutes before
measurements,inaquiet,temperature-controlled(21–24◦C)
room with dimmed lights. The subjects were asked to remain
as still as possible and silent during the entire measurement
period. Each recording consisted of 5 minutes of baseline
measurement, 5 minutes of occlusion measurement, and
5 minutes postocclusion measurement (hyperemic period).
Occlusion of the brachial artery was performed on the
nondominant upper arm. The occlusion pressure was at
least 60mmHg above the systolic blood pressure (minimally
200mmHg, and maximally 300mmHg).
2.2. Renal Patient Study Part. Endothelial function and
arterialstiﬀnesswereinvestigatedinsixpatientswithchronic
kidney failure (subject characteristics in Table 1, glomerular
ﬁltration rate was estimated by calculation of creatinine
clearance using a 24-hour urine collection). All subjects were
on maintenance therapy for treatment of hypertension. All
measurements were performed in the morning. Per subject,
3 measurements were performed, separated by one to two
weeks. Patients were allowed to use medication needed
for their medical condition, except for corticosteroids and
erythropoietic medication within one month before study
participation.
2.3. Diabetic Patient Study Part. Endothelial function and
arterial stiﬀness were investigated in 16 patients with dia-
betes mellitus type 2 (subject characteristics in Table 2).
All subjects were on oral antidiabetics to control glucose
metabolism: 8 subjects were using metformin, and 8 subjects
were using metformin plus sulfonylurea. Per subject, two
EndoPAT measurements were performed: one time during
continuation of the antidiabetic therapy and one time after
two weeks of therapy discontinuation, with the sequence
randomized. All measurements were performed in the
evening. Patients were allowed to use medication needed
for their medical condition, except for medication known
to aﬀect glucose homeostasis (other than biguanides and
sulphonylurea), anti-inﬂammatory drugs, nonselective beta
blockers, oral anticoagulants, and systemic glucocorticoids
or other immunosuppressive drugs.International Journal of Vascular Medicine 3
Table 1: Renal patients, baseline characteristics.
Subject Gender Age (years) BMI (kg/m2) GFR (mL/min) BP (mmHg) HR (bpm) Maintenance therapy
1 M 59 24 45 140/83 63 a, b, c
2 M 63 27 47 134/82 54 a, c, d, e, f, g
3 F 57 20 41 138/61 67 a, c, e, h, i
4 F 46 19 51 120/73 58 b, h
5 F 59 22 55 150/86 64 a, c
6 M 65 32 69 140/75 75 a, b, j
astatin, bcalcium channel blocker, cACE inhibitor, dthiazide diuretic, eplatelet aggregation inhibitor, fangiotensin II receptor antagonist, gintestinal potassium
binder, hpotassium chloride, iacetylsalicylic acid, and jβ1r e c e p t o rb l o c k e r .
BP: blood pressure (supine).
BMI: body mass index.
GFR: glomerular ﬁltration rate.
HR: heart rate (supine).
Table 2: Diabetic patients, baseline characteristics.
Metformin group Metformin plus sulfonylurea group
Number (male/female) 8 (7/1) 8 (8/0)
Age (years) 56 ±85 8 ±6
BMI (kg/m2)2 7 ±32 7 ±4
Systolic BP (mmHg) 137 ±7 142 ± 7
Diastolic BP (mmHg) 83 ±67 9 ±8
HR (bpm) 70 ±97 4 ±11
Glucose (mM) 6.3 ±0.86 .8 ±3.2
HbA1c (mM) 6.4 ±0.56 .1 ±0.6
(Mean ± SD).
BP: blood pressure (supine).
BMI: body mass index.
HR: heart rate (supine).
2.4. Oral Glucose Intervention in Healthy Volunteers. Six
nonsmoking female subjects (mean age 23 ± 3y e a r s )p a r -
ticipated in the oral glucose intervention study part. After
the baseline EndoPAT measurement was performed, an oral
glucose solution (75g glucose in 300mL) was consumed
within 4 minutes. At 30 minutes and 90 minutes after the
oral glucose consumption, EndoPAT measurements were
performed.
2.5. Smoking Intervention in Healthy Volunteers. Six male
cigarette smoking subjects (mean age 32 ± 10 years) par-
ticipated in this study part. The number of cigarettes per
subject per day ranged between 1 and 20 cigarettes. Subjects
refrained from smoking until at least 2 hours before the start
of the study. After a baseline measurement was performed,
the participants smoked a cigarette (tar 10mg, nicotine
0.8mg and carbon monoxide 10mg) within 4 minutes. At
30 minutes and 90 minutes after smoking, the measurements
were repeated.
2.6. Data Analysis and Statistics. Unpaired t-tests were used
to compare RHI and AI between healthy volunteers and
patients and between diabetic patients using metformin only
andpatientsusingmetforminplussulfonylurea,whilepaired
t-tests were used to compare RHI and AI between diabetic
patients who continued their medication and patients who
discontinued their medication. The intervention experi-
ments were carried out in groups of 6 healthy volunteers; a
sample size based on the observed intraindividual variability
in RHI and the level of impairment of endothelial function
determined by conventional techniques (high-resolution
ultrasound, plethysmography) in intervention studies as
reported in literature. Our experiments were powered such
that a group size of 6 would have 80% power to detect a 25%
change in baseline RHI using a 2-sided alpha of 5%. Paired
t-tests were used to compare the diﬀerence in RHI between
baseline and the postintervention measurements, which was
considered to be statistically signiﬁcant when P value < 0.05.
3. Results
To assess the performance of the EndoPAT, we investigated
the variability of endothelial function (RHI) and arterial
stiﬀness (AI) in patients with chronic kidney failure on three
diﬀerent days, separated by one to two weeks. Average RHI
over three days was 2.9 ± 1.4( T a b l e3). For most patients,
the RHI values exceeded a value of 2 (range: from 1.7 to
5.5). Oﬃcial reference values for RHI are not available, but
in general RHI values below 2 are categorized as endothelial
dysfunction, whereas higher RHI values are considered
normal or improved endothelial function (Itamar product
information). The average intra-individual variability for4 International Journal of Vascular Medicine
Table 3: Reactive hyperaemia index.
Population N Therapy Study period mean ± SD min–max CV
Renal patients 6 N/A N/A# 2.9 ±1.4 1.7–5.5 50%
Diabetic patients 8 Metformin Cont. 1.8 ±0.3 1.5–2.2 16%
Diabetic patients 8 Metformin Discont. 1.8 ±0.4 1.1–2.4 25%
Diabetic patients 8 Metformin + SA Cont. 2.5 ±0.7∗,∗∗ 1.7–3.7 28%
Diabetic patients 8 Metformin + SA Discount. 2.7 ±1.1∗,∗∗ 1.7–4.9 41%
Healthy volunteers 12 N/A N/A 1.8 ±0.5 1.3–2.8 29%
SA: sulfonylurea; SD: standard deviation; CV: coeﬃcient of variation.
Cont: continuation of therapy; discount: 2 weeks of therapy discontinuation.
#visit 1, 2, and 3 and averaged (see materials and methods).
∗P<0.05 versus healthy volunteers.
∗∗P<0.05 versus diabetic patients on metformin only.
Table 4: Augmentation index.
Population N Therapy Study period mean ± SD min–max
Renal patients 6 N/A N/A# 26.1 ± 13.9∗ 13.3–52.0
Diabetic patients 8 Metformin cont 5.9 ±9.4∗∗ −8.0–22.0
Diabetic patients 8 Metformin discont 14.3 ±18.9∗∗ 1.0–55.0
Diabetic patients 8 Metformin + SA cont 9.0 ±13.0∗∗, ∗∗∗ −15.0–24.0
Diabetic patients 8 Metformin + SA discont 16.3 ±16.0∗∗, ∗∗∗ −6.0–32.0
Healthy volunteers 12 N/A N/A −6.0 ±14.2 −25.7–31.7
SA: sulfonylurea; SD: standard deviation.
Cont: continuation of therapy; discount: 2 weeks of therapy discontinuation.
#visit 1, 2, and 3 and averaged (see materials and methods).
∗P = 0.001 versus healthy volunteers.
∗∗P<0.05 versus healthy volunteers.
∗∗∗P<0.05 versus diabetic patients on metformin only.
the RHI was 13% (ranging from 1% to 29% for individuals,
data not shown). The general estimate for interindividual
variability in RHI was 50% (Table 3). Average AI over three
days was 26.1 ± 13.9( T a b l e4). This is in line with the
expectation, as normal arterial stiﬀness is deﬁned by an AI
between −30% and −10%, increased arterial stiﬀness by an
AI between −10% and 10%, and abnormal arterial stiﬀness
by an AI above 10%. The mean intra-individual coeﬃcient
of variation was 37% (ranging from 13% to 67%, data
not shown). These data indicate that whereas endothelial
function is a relatively stable measure over a longer period
of time, arterial stiﬀness as determined by the EndoPAT is
rather variable.
Next, we measured endothelial function and arterial
stiﬀness in patients with diabetes mellitus type 2, 8 subjects
using metformin and 8 subjects using metformin plus
sulfonylurea. Endothelial function and arterial stiﬀness were
determined during continuation of the antidiabetic therapy
and after two weeks of therapy discontinuation. Arterial
stiﬀness, as determined by AI, was not diﬀerent between
patients using metformin or metformin plus sulfonylurea or
between patients continuing and discontinuing antidiabetic
medication (Table 4:5 .9 ± 9.4v e r s u s9 .0 ± 13.0a n d
14.3 ± 18.8v e r s u s1 6 .3 ± 16.0, resp.). However, RHI
was signiﬁcantly higher in patients using a combination of
metformin plus sulfonylurea, compared to patients using
metformin only (Table 3:2 .5 ± 0.7v e r s u s1 .8 ± 0.3i n
patients continuing therapy and 2.7 ± 1.1v e r s u s1 .8 ± 0.4
in patients discontinuing therapy; P = 0.02 and 0.04 resp.).
The increasing eﬀe c to fs u l f o n y l u r e at r e a t m e n to nR H Iw a s
independent on continuation or discontinuation of the use
of antidiabetics.
Finally, we investigated the capability of the EndoPAT
to detect changes in endothelial function induced by two
acute interventions in healthy volunteers. Neither the oral
glucose load nor the smoking intervention resulted in
signiﬁcant eﬀects on endothelial function (Figure 1). For the
glucose intervention, the diﬀerence in RHI from baseline
measurement was 0.08 ± 0.50 (95% CI, conﬁdence interval:
from −0.44to0.60)forthe30minassessmentand0.44±0.86
(95% CI: from −0.46 to 1.34) for the 90min assessment.
For the smoking intervention, the diﬀerence in RHI from
baseline measurement was 0.49 ± 0.92 (95% CI: from −0.47
to 1.46) for the 30min assessment and 0.39 ± 0.53 (95% CI:
from −0.16 to 0.95) for the 90min assessment.
AI and RHI were compared between the investigated
patient groups and the healthy volunteer group. As expected,
AI was higher in renal patients compared to healthy subjects
(Table 4:2 6 .1 ± 13.9i np a t i e n t sv e r s u s−6.0 ± 14.2i n
healthy volunteers, P = 0.001). AI was also higher in
diabetic patients compared to healthy subjects, independent
of type of oral antidiabetics (metformin or metformin plus
sulfonylurea) or continuation or discontinuation of therapy
(Table 4:5 .9 ± 9.4, 9.0 ± 13.0, 14.3 ± 18.8, and 16.3 ± 16.0,International Journal of Vascular Medicine 5
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Figure 1: Interventions and endothelial function. Reactive hyper-
emia index was assessed before and at 30 and 90 minutes after an
oral glucose load (left) or after cigarette smoking (right).
resp., in patients versus −6.0 ± 14.2 in healthy volunteers,
0.01 <P<0.05). However, there was no diﬀerence in
RHI between the renal patients and the healthy volunteers
(Table 3:2 .9 ± 1.4 in patients versus 1.8 ± 0.5i nh e a l t h y
volunteers, P = 0.15). Furthermore, RHI values did not
diﬀerbetweendiabeticpatientsusingmetforminandhealthy
volunteers (Table 3:1 .8 ± 0.3 in patients continuing therapy
and 1.8 ± 0.4 in patients discontinuing therapy versus 1.8 ±
0.5 in healthy volunteers). RHI was signiﬁcantly higher in
diabetic patients using a combination of metformin plus
sulfonylurea compared to healthy volunteers (Table 3:2 .5 ±
0.7 in patients continuing therapy and 2.7 ± 1.1i np a t i e n t s
discontinuingtherapy;P = 0.04and0.01resp.versushealthy
volunteers).
4. Discussion
Endothelial dysfunction is present in several systemic
pathological conditions [5–9], associated with considerable
morbidity and mortality. As a consequence, endothelial
dysfunction is expected to gain interest as potential target
for (pharmaceutical) intervention within the coming years.
Currently, endothelial function is assessed mainly by high-
resolution ultrasound of the brachial artery. However, this
technique has important practical limitations: it is strongly
operator-dependent [11], and it oﬀers no correction for
autonomous activation of the nervous system, as vascular
dilation is only studied in one arm. To overcome these
problems,theEndoPATwasdeveloped,allowingnoninvasive
measurement of endothelial function via assessment of
reactive hyperemia. In addition, the EndoPAT provides a
measure for arterial stiﬀness. Although in several stud-
ies the EndoPAT appeared to be feasible to demonstrate
improvement of endothelial function as a result of lifestyle
modiﬁcation or pharmacological intervention [19–24], the
informationinliteratureontheperformanceoftheEndoPAT
in intervention trials is limited. Therefore, we performed
a series of experiments to investigate the feasibility of the
EndoPAT to evaluate acute changes in endothelial function
withrepeatedmeasurementsandtoassessthediscriminating
power of the EndoPAT for endothelial function and arterial
stiﬀness in diﬀerent populations.
We assessed the variability of endothelial function (by
RHI) and arterial stiﬀness (by AI), as measured by the
EndoPAT, in patients with impaired renal function on three
diﬀerent days. Next, we measured endothelial function and
arterial stiﬀness in patients with diabetes mellitus type 2.
Finally, we investigated the applicability and feasibility of the
EndoPATtodetectchangesinendothelialfunctioninhealthy
volunteers after interventions known to be associated with
robustacutechangesinendothelialfunctioninanadequately
powered experiment.
Generally, augmentation index, calculated from carotid,
aortic, or radial artery pressure waves using conventional
techniques, is a reliable and reproducible measure to deﬁne
arterial stiﬀness [35]. However, the inﬂuence of variables
such as heart rate and vasomotor tone of the arterial
system can aﬀect the variability of the technique [36]. We
demonstrated that when using the EndoPAT, the intra-
individual variability in AI was substantial over a longer
period of time (CV: coeﬃcient of variation, 37%). This
indicatesthatarterialstiﬀnessasdeterminedbytheEndoPAT
is also not a stable measure, which limits its usefulness
to assess the eﬀects of (pharmacological) interventions.
Arterial stiﬀness as measured by the EndoPAT was higher in
renally impaired patients with vascular disease compared to
healthy subjects. This is in line with reports in literature in
patient populations: compared to healthy volunteers, arterial
stiﬀness is increased in a variety of pathological conditions,
such as coronary artery disease, metabolic syndrome, and
chronic kidney disease [37–39].
Compared with arterial stiﬀness, RHI proved to be a
more stable measure (CV 13%). Surprisingly, endothelial
function,asdeterminedbyreactivehyperemiaindex,wasnot
impaired in the renal patient group. Importantly, observed
RHIs in the patient population were scattered over a
broad range, covering both endothelial dysfunction (RHI
< 2) and exceptionally good endothelial function (RHI >
3). Given the fact that all subjects were renally impaired
and treated for hypertension, it is very unlikely that 4
out of 6 patients had an (exceptionally) good endothelial
function. Obviously, all patients used medication with per-
tinent eﬀects on endothelial function (Table 1: statins, ACE
inhibitors, and calcium channel blockers) [40], but literature
data suggest that despite optimal (cardiovascular) therapy,
a considerable increased risk for cardiovascular morbidity
in this population still exists [41]. Importantly, although
most chronic kidney disease patients use antihypertensive
medication and other drugs that could aﬀect endothelial
function (statins, potassium, and ACE inhibitors), they
still exhibit a signiﬁcantly impaired endothelial function as
demonstrated by laser Doppler ﬂowmetry (32% reduction)
[25]. Interestingly, Gordon et al. reported that pulse contour
analysis obtained by ﬁnger plethysmography, which is com-
parable with the EndoPAT methodology, may not be suitable6 International Journal of Vascular Medicine
to measure endothelial function in subjects with extensive
coronary artery disease, as no eﬀect of administration of
strong vasodilators (salbutamol and nitroglycerin) could be
observed [42].
WeinvestigatedwhethertheEndoPATcoulddiscriminate
in vascular function between healthy volunteers and patients
with diabetes mellitus type 2. As expected, arterial stiﬀness
was higher in diabetic patients compared to healthy subjects,
irrespective of treatment with oral antidiabetics. However,
endothelial function (as measured by the EndoPAT) was not
impaired in diabetic patients using metformin compared to
healthy volunteers, neither during continuation of treatment
nor after two weeks of treatment discontinuation. This
is contrasting with literature, which demonstrates that
endothelial function, measured using conventional tech-
niques (endothelium-dependent ﬂow-mediated dilatation of
the brachial artery, by ultrasound), is substantially impaired
in diabetic patients (reduction of endothelial function versus
healthy controls or subjects with coronary artery disease
without diabetes ranging from 27% to 43%) [29–31]. This
discrepancy could not be explained by an eﬀect of treatment
with oral antidiabetics, as RHI was assessed both during
treatment continuation and after a two-week period of
treatment discontinuation.
RHI was signiﬁcantly increased in patients using a
combination of metformin plus sulfonylurea, compared to
healthy volunteers and to patients using metformin only.
This stimulating eﬀect of sulfonylurea treatment on RHI was
still observed after two weeks of treatment discontinuation,
implicating a long-lasting eﬀect of sulfonylurea on endothe-
lial function. This is remarkable as the general point of
view is that the use of pancreatic β-cell-speciﬁc sulfonylurea
(i.e., glimepiride, as used by 6 out of 8 diabetic subjects
in our study) does not aﬀect endothelial function [43–45].
Possibly, endothelial function as measured by the EndoPAT
(RHI) is a physiologically diﬀerent process than endothelial
function as measured by conventional techniques such as
high-resolution ultrasound (endothelium-dependent FMD).
T h ee x a c tn a t u r eo ft h i sd i ﬀerence is currently unknown,
and should be investigated in detail before the EndoPAT can
be considered a useful tool in drug development or clinical
practice.
We evaluated the performance of the EndoPAT to detect
the eﬀects of two diﬀerent acute interventions on RHI in
healthy subjects. The literature shows that FMD decreases
by 40–65% after smoking one cigarette, which is detected
directly after smoking and lasts for 1 hour [2, 32, 46, 47].
Also hyperglycaemia, induced by the administration of a
standardised oral glucose load, has been reported to acutely
lead to a 25–45% impairment of endothelial function, as
assessed by FMD or forearm blood ﬂow plethysmography
[33, 34, 48]. However, we were unable to replicate these
ﬁndingsonendothelialfunctionusingtheEndoPAT,demon-
strating that the device is currently not suitable to detect
acute changes in endothelial function after diﬀerent robust
interventions. There could be several explanations for our
ﬁndings. In the automated analysis, the EndoPAT software
uses a ﬁxed time frame during the hyperemic response to
calculatetheRHI.Inspectionofthedataandmanualanalysis
of the RHI showed that the maximal hyperemic response
doesnotalwaysoccurinthesametimeperiodafterocclusion
(data not shown), an observation that is supported by
literature. For example, the time course of FMD is strongly
inﬂuenced by age: comparison of young and older subjects
indicatesthatthetimeframetoreachmaximalvasodilatation
after occlusion is signiﬁcantly prolonged in older subjects
[49]. This may be remedied by reﬁnement of the EndoPAT
software to allow for interindividual diﬀerences in hyper-
emic time course. Although inter-individual diﬀerences in
hyperemic time course is a potentially confounding factor
when using the automatic analysis, manual analysis of our
datadidnotresultinsigniﬁcantlydiﬀerentﬁndings(datanot
shown).Therearesomeindicationsthatendothelialfunction
is subject to a circadian rhythm, with a lower reactive
hyperemic response in the morning [50] ,b u tt h i si sn o t
unambiguously supported [51–54]. In fact, the presumed
circadian variability is probably more related to changes
in physical activity, blood pressure and shear stress, and
changes in plasma lipids. Whatever the explanation may
be, our experiments were performed within a short ﬁxed
time frame of maximally 2 hours, in a fasted condition
and in complete rest, thereby reducing the inﬂuence of
these confounding factors. As a consequence, it is unlikely
that circadian variability has inﬂuenced our measurement
outcomes. Finally, it is possible that previous experiments
using ultrasound or plethysmography to assess the acute
eﬀect of an intervention on endothelial function are ﬂawed
b e c a u s em e a s u r e m e n t sw e r ep e r f o r m e d( i nt h em a j o r i t yo f
the cases) in the vasculature of one arm only, and thus
relatively uncontrolled for concomitant systemic hemody-
namic changes. We consider this a theoretical explanation,
but unlikely. We are well aware that the group sizes of our
intervention experiments were small and that no formal
control groups were included. However, the experiments
were suﬃciently powered to detect intervention-induced
changes in endothelial function at eﬀect sizes that are
reported in literature using FMD or forearm blood ﬂow
plethysmography.
In conclusion, whereas the reactive hyperemia index (a
measure for endothelial function), as determined by the
EndoPAT, is rather stable over time, the augmentation index
(a measure for arterial stiﬀness) showed substantial intra-
individual variability, limiting its value for evaluation of
(pharmacological) interventions. Surprisingly, the EndoPAT
did not demonstrate diﬀerences in endothelial function
between healthy volunteers and renally impaired patients
with known vascular disease or diabetic patients. In the
latter patient group, an unexplained improving eﬀect of sul-
fonylurea on reactive hyperemia index was demonstrated by
the EndoPAT. This could indicate that endothelial function
as measured using the EndoPAT might be physiologically
diﬀerent from endothelial function as measured by conven-
tional techniques. Furthermore, the EndoPAT was not useful
to detect the eﬀect of robust interventions on endothelial
function while the experiments were adequately powered.
Taken together, our ﬁndings suggest that the EndoPAT is
at present not suitable to assess (changes in) endothelialInternational Journal of Vascular Medicine 7
function and arterial stiﬀness in populations with sizes that
are commonly employed in clinical pharmacology studies.
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